Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Modus Therapeutics publishes interim report for the second quarter 2022

STOCKHOLM, SWEDEN - 23 August 2022: Modus Therapeutics Holding AB (” Modus Therapeutics”) hereby publishes an interim report for the second quarter 2022. The report is available as an attached document and on the company's website (www.modustx.com/investors/financial-reports.html). Below is a summary of the interim reportThe second quarter in figures · The loss after tax amounted to TSEK 2 992 (2 533). · The loss per share amounted to SEK 0,19 (0,26). · The cash flow from current operations was negative in the amount of TSEK 3 228 (2 299). The first half-year in figures ·

Q2 Report – 30 June 2022

Flexion Mobile reports new growth record and hits USD 20 million revenue milestone for the quarter. Gross profit soars by 211% resulting in adjusted EBITDA[‡] of GBP 1.4 million.April-June 2022 performance · Total revenue increased by 127% to GBP 17.7m (7.8)* · Gross profit increased by 211% to GBP 2.9m (0.9) · Adjusted EBITDA[‡] increased to GBP 1.4m (0.02) · Operating result decreased to GBP -0.4m (-0.05) · Earnings per share amounted to GBP -1.42 pence  (-0.13 pence) · Cash and cash equivalents amounted to GBP 8.4m (15.6) January-June 2022 performance · Total

Alleima hosts its first Capital Markets Day

Alleima, formerly Sandvik Materials Technology, which is expected to be listed on Nasdaq Stockholm, today hosts its first Capital Markets Day, in Sandviken, Sweden. At the event, the executive management will present trends and characteristics of the Alleima markets, business, financial performance, and strategic direction. Alleima advances industries through materials technology. Alleima offers niched and premium products to a wide set of industries and has claimed strong market positions through its leading metallurgy expertise, global reach, and fully integrated value chain. The

Alleima hosts its first Capital Markets Day

Alleima, formerly Sandvik Materials Technology, which is expected to be listed on Nasdaq Stockholm, today hosts its first Capital Markets Day, in Sandviken, Sweden. At the event, the executive management will present trends and characteristics of the Alleima markets, business, financial performance, and strategic direction.Alleima advances industries through materials technology. Alleima offers niched and premium products to a wide set of industries and has claimed strong market positions through its leading metallurgy expertise, global reach, and fully integrated value chain. The

Bioretec’s ActivaPin™ bioresorbable implant provides good alternative treatment of pediatric elbow injuries

Bioretec Ltd          Press release          23 August 2022 at 9 a.m. EESTA recently published clinical study confirms the benefits of using fully bioresorbable ActivaPin™ implant together with bioabsorbable suture, for the tension band wire treatment of pediatric medial epicondyle humeral fractures. A tension band wire is a form of orthopaedic internal fixation method used to convert distraction forces into compression forces, promoting bone healing. The results of the retrospective cohort study shows that patients treated with bioresorbable ActivaPin™ were provided a good alternative

Calmark Sweden AB (publ) decides on the issue of units of approximately SEK 26.1 million with preferential rights for existing shareholders, subject to the subsequent approval of the general meeting

The board of directors of Calmark Sweden AB (publ) (“Calmark” or the “Company”) has today, conditioned by the Extraordinary General Meeting’s approval on September 22, 2022, decided on an issue of units consisting of shares and warrants with preferential rights for Calmark’s existing shareholders (“Rights issue”) of approximately SEK 26.1 million. The Rights Issue is covered by a maximum of 16,333,192 B shares and 4,083,298 warrants (units). The proceeds shall primarily finance sales and marketing efforts in connection with the commercialization of the Company’s products. About 80 percent of

Zwipe H1 2022 results – healthy commercial momentum

OSLO, NORWAY – 23 August 2022 – Zwipe AS ("Zwipe" or "the company") today announces its results for the first half 2022.   Operational highlights · Visa certifies Zwipe Pay Biometric Payment Card (“BPC”) Platform and issues Letter of Approval (“LoA”) to Zwipe.   · Beautiful Card Corporation (“BCC”), TAG Systems and Inkript obtain Visa LoAs for their own card built on the Zwipe Pay platform.   · Fraport AG, providing operational services to 31 airports globally, selected Zwipe Access as one of two solutions to test in a pilot of next generation access control

Interim report April-June 2022

Outcome April - June · Net sales amounted to  111 (492) kSEK · Profit after net financial items amounted to  -4 963 (-3 638) kSEK · Basic and diluted earnings per share -0,38 (-0,28) kSEK · Cash flow from operating activities and investing activities -5 576 (-1 678) kSEK Significant events April-June · Annual General Meeting was held in April. The AGM resolved on all points in accordance with the Board's and the Nomination Committee's proposals · A large university in the United Kingdom has purchased an Insplorion M8 instrument to expand on their cutting-edge

Green Landscaping Group strengthens its presence in Norway through acquisition of Braathen Landskapsentreprenør AS

23 August 2022 – 08:00 CEST Green Landscaping Group AB (publ) has signed an agreement to acquire Braathen Landskapsentreprenør AS with a turnover of approximately NOK 300 million.Braathen Landskapsentreprenør was founded in 1968 and is today one of Norway's largest landscaping companies. The company offers a complete range of services in landscaping, land construction, infrastructure and maintenance of outdoor environments. The company employs approximately 180 employees, has its headquarters in Ytre Enebakk and carries out work mainly in the Oslo region. - Braathen

Isofol Medical AB (publ) publishes interim report, January–June 2022

GOTHENBURG, Sweden, August 23, 2022 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January–June 2022 is now available on the company's website, www.isofolmedical.com.The information in the press release is intended for investors. Second quarter, April–June 2022 · Net revenue amounted to TSEK 4,027 (7,333) and other revenue to TSEK 0 (0) · The result for the period amounted to TSEK -54,033 (-45,394) · Earnings per share amounted to SEK -0.33 (-0.48) · Cash and cash equivalents at June 30 amounted to TSEK 277,727 (

Implantica publishes Interim Report Q2 2022

Executing on RefluxStop™ Commercialisation StrategySignificant events in the second quarter of 2022 · Implantica has completed the first AppetiteControl™ food sensor clinical trial on 20 human volunteers. The results are currently being evaluated. · Implantica successfully conducted its first User Meeting with 11 highly experienced anti-reflux Key Opinion Leaders (KOLs) participating, from several European countries. The purpose of the meeting was to standardize the surgical technique for the RefluxStop™ procedure. A consensus paper has been written and will be published. ·

Etteplan Oyj Announces a Recommended Cash Offer of SEK 149 per Share to the Shareholders of Semcon AB

ETTEPLAN OYJ, Stock Exchange Release, Inside information, 23 August 2022, 09.00 a.m. EEST THIS ANNOUNCEMENT IS NOT AN OFFER, WHETHER DIRECTLY OR INDIRECTLY, IN AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA OR THE UNITED STATES OR IN ANY OTHER JURISDICTION WHERE SUCH OFFER PURSUANT TO LEGISLATION AND REGULATIONS IN SUCH RELEVANT JURISDICTION WOULD BE PROHIBITED BY APPLICABLE LAW. SHAREHOLDERS NOT RESIDENT IN SWEDEN WHO WISH TO ACCEPT THE OFFER (AS DEFINED BELOW) MUST MAKE INQUIRIES CONCERNING APPLICABLE LEGISLATION AND POSSIBLE TAX CONSEQUENCES. SHAREHOLDERS SHOULD REFER

EBIT profitability in Q2 despite tough macro environment

LMK Group, a leading supplier of meal kits in the Scandinavian region and a leader in Scandinavian foodtech, today announced its financial results for the second quarter 2022. The Group operates in Sweden, Norway and Denmark under the brands Linas Matkasse, Godtlevert, Adams Matkasse and RetNemt.CEO Walker Kinman commented: “Accelerating inflation and declines in consumer sentiment on recessionary fears, combined with changes in customer behavior as the economy continues to emerge from the Covid pandemic, continued to affect demand for the category negatively during the second quarter.

Pagero publishes interim report for Q2 2022: Strong second quarter with increased growth

Pagero Group AB (publ) publishes interim report for the period January-June 2022“Increasing legislation demanding digital reporting and document transfer in various countries, combined with the growing trend to intensify automation of administrative tasks, have had a continued positive impact on the overall market trend. Pagero’s ARR increased by 49% and total net sales increased by 46%. Several of our investment markets show good growth and our offer “One connection – global reach” continues to gain market shares”, says Bengt Nilsson, CEO at Pagero. Second quarter of 2022 · Net

Share buy-backs in Telia Company during week 33 2022

Telia Company AB (publ) (LEI code 213800FSR9RNDUOTXO25) has repurchased own shares (ISIN: SE0000667925) as specified in the table below. The share buy-backs form part of the SEK 5.4 billion share buy-back program that Telia Company announced on June 1, 2022 . The share buy-back program is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 (“MAR”) and the Commission Delegated Regulation (EU) No 2016/1052 (the “Safe Harbour Regulation”)

Tobii Interim Report for the second quarter 2022

Tobii AB (publ) today announced its results for the second quarter of 2022. Comment by Tobii’s CEO Anand Srivatsa: “Tobii delivered a strong quarter, reaching 21 percent organic revenue growth, enabling us to deliver an all-time high Q2 revenue and improvements in profitability. More importantly, our underlying long-term business dynamics were very encouraging as we made significant strides in several investment initiatives. A noteworthy example was the Sony PS VR2 contract, proving that our investments and perseverance in VR and AR are on the right track.” Second quarter April –

Interim Report for the Period April 1, 2022, to June 30, 2022

April – June 2022 in Summary •         Net Revenue of SEK 462.8 (311.1) million, representing a 48.8 percent growth. Notably, the growth was largely organic with 40.9 percent organic growth rate for the quarter and 23.6 percent in local currencies. •         EBITDA of SEK 88.3 (68.8) million, representing an increase of 28.2 percent. •         Adjusted EBITDA of SEK 84.3 (81.1) million, corresponding to a growth of 3.9 percent and 18.2 percent margin. The adjustment for non-recurring items affecting EBITDA in the second quarter comparability of SEK 4.0 million was primarily non-

American Shipping Company ASA - Second quarter 2022 results

Lysaker, 23 August 2022, American Shipping Company ASA (“AMSC” or the “Company”) announces results for the second quarter ending 30 June 2022. HIGHLIGHTS · Stable financial performance with bareboat revenue of USD 22.0 million, normalized EBITDA of USD 20.9 million and adjusted net profit of USD 3.8 million · On 12[th] May, AMSC reported an agreement to acquire the offshore construction vessel Normand Maximus and to enter into a long- term bareboat charter commencing in Q4 2022 to a subsidiary of Solstad Offshore ASA · On 10[th] June, AMSC announced two new multi-year Jones

BerGenBio reports second quarter and half year 2022 financial results and provides business update

- Commenced bemcentinib Phase 2b trial in hospitalized COVID-19 patients - - Initiation of Phase 1a/2b STK11 mutated NSCLC trial planned for 2H22 - - BerGenBio to host conference call and webcast today at 10:00 AM CEST/4:00 AM EDT -   BERGEN, Norway, August 23, 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the second quarter and half year ended June 30, 2022 and provided a business update.   “The prioritization of

Exercise of Camurus’ subscription warrant program 2019/2022

Lund, Sweden — 23 August 2022 — During August 2022, a total of 301,200 subscription warrants in Camurus AB’s warrant program 2019/2022 have been exercised for the corresponding number of shares, at an exercise price of SEK 98.90 per share. Through the exercise of the subscription warrants Camurus receives SEK 29,788,680. A number of employees and senior executives of Camurus, including the company’s CEO, have participated and have in a cashless exercise sold shares to finance the subscription of new shares and taxes related to the transaction. As a result of the transactions, the total

Operational EBIT of DKK 1,004 Million for the First Half of 2022

(Figures in parenthesis refer to the same period last year unless otherwise specified) The Bakkafrost Group delivered a total operating EBIT of DKK 587 million (DKK 407 million) in Q2 2022 and made a profit of DKK 845 million (DKK 428 million). The combined FO farming and VAP segments made an operational EBIT of DKK 509 million (DKK 348 million). The FO farming segment made an operational EBIT of DKK 617 million (DKK 343 million). The SCT farming segment made an operational EBIT of DKK 41 million (DKK 53 million). The VAP segment made an operational EBIT of DKK -108 million (DKK 5 million).

Nordea Bank Abp: Repurchase of own shares on 22.08.2022

Nordea Bank AbpStock exchange release – Changes in company’s own shares22.08.2022 at 22.30 EET Nordea Bank Abp (LEI: 529900ODI3047E2LIV03) has on 22.08.2022 completed repurchases of own shares (ISIN: FI4000297767) as follows: Trading Number of Weighted average Total cost, EUR* **venue (MIC shares price / share, EUR* Code) **XHEL 350,000 9.42 3,295,390.00CEUX 360,000 9.41 3,389,360.00TQEX 0 - 0.00XSTO 400,000 9.42 3,767,

There are no items matching the current filter
There are no more items matching the current filter
Back to top